Managing Patients With Relapsed Small-Cell Lung Cancer

被引:42
|
作者
Gong, Jun [1 ]
Salgia, Ravi [1 ]
机构
[1] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
PHASE-II TRIAL; OPEN-LABEL; 3RD-LINE CHEMOTHERAPY; 2ND-LINE CHEMOTHERAPY; AMERICAN-COLLEGE; TOPOTECAN; MULTICENTER; IRINOTECAN; MANAGEMENT; TEMOZOLOMIDE;
D O I
10.1200/JOP.18.00204
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite high response rates to initial therapy, relapses are common in patients with small-cell lung cancer (SCLC). Systemic therapy after first-line failure remains important in the treatment paradigm of SCLC. Reinitiation of a previously administered first-line chemotherapy regimen is recommended for relapse > 6 months from completion of initial therapy. For relapse 6 months of initial therapy, sequential therapy with single agents is recommended. Clinical trial enrollment should be considered at all stages of treatment of SCLC. This review highlights the available treatment options in relapsed SCLC. In particular, we focus on prospective clinical trials demonstrating activity for the most commonly used agents in this setting. We end with a discussion on future directions and emerging targets with potential to improve outcomes in relapsed SCLC.
引用
收藏
页码:359 / +
页数:9
相关论文
共 50 条
  • [1] Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer
    Garst, Jennifer
    Buller, Richard
    Lane, Stephen
    Crawford, Jeffrey
    CLINICAL LUNG CANCER, 2005, 7 (03) : 190 - 196
  • [2] Combination chemotherapy for relapsed small-cell lung cancer
    Kalemkerian, Gregory P.
    LANCET ONCOLOGY, 2016, 17 (08): : 1033 - 1035
  • [3] Gefitinib efficacy in relapsed small-cell lung cancer
    Dincer, Murat
    Aksoy, Sercan
    Kilickap, Saadettin
    Altundag, Kadri
    LUNG CANCER, 2006, 53 (02) : 255 - 255
  • [4] Treatment options for relapsed small-cell lung cancer
    Azim, Hatem A., Jr.
    Ganti, Apar Kishor
    ANTI-CANCER DRUGS, 2007, 18 (03) : 255 - 261
  • [5] Amrubicin hydrochloride for relapsed small-cell lung cancer
    Byron, Elizabeth
    Chiappori, Alberto
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (12): : 1041 - 1047
  • [6] Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias
    Saijo, Atsuro
    Hanibuchi, Masaki
    Ogino, Hirokazu
    Otsuka, Kenji
    Goto, Hisatsugu
    Nokihara, Hiroshi
    Nishioka, Yasuhiko
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (05) : 541 - 546
  • [7] Relevance of Platinum Sensitivity in Patients with Relapsed or Refractory Small-Cell Lung Cancer
    Kim, Young Hak
    Mishima, Michiaki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) : E35 - E35
  • [8] A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer
    Shibayama, Takuo
    Hotta, Katsuyuki
    Takigawa, Nagio
    Tada, Atsuhiko
    Ueoka, Hiroshi
    Harita, Shingo
    Kiura, Katsuyuki
    Tabata, Masahiro
    Segawa, Yoshihiko
    Nogami, Naoyuki
    Kuyama, Shoichi
    Shinkai, Tetsu
    Tanimoto, Mitsune
    LUNG CANCER, 2006, 53 (02) : 189 - 195
  • [9] Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
    Farago, Anna F.
    Yeap, Beow Y.
    Stanzione, Marcello
    Hung, Yin P.
    Heist, Rebecca S.
    Marcoux, J. Paul
    Zhong, Jun
    Rangachari, Deepa
    Barbie, David A.
    Phat, Sarah
    Myers, David T.
    Morris, Robert
    Kem, Marina
    Dubash, Taronish D.
    Kennedy, Elizabeth A.
    Digumarthy, Subba R.
    Sequist, Lecia V.
    Hata, Aaron N.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Lawrence, Michael S.
    Shaw, Alice T.
    Mino-Kenudson, Mari
    Dyson, Nicholas J.
    Drapkin, Benjamin J.
    CANCER DISCOVERY, 2019, 9 (10) : 1372 - 1387
  • [10] Is relapsed small-cell lung cancer (SCLC) under treated?
    Nicum, S.
    Ashley, S.
    O'Brien, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 377 - 377